DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS ⚠️ Small Study / Early Comparative Evidence
The Phase 3 INVEST-HD trial of oral votoplam dosed its first patient, enrolling up to 770 early-stage Huntington’s patients. Interim Phase 2 extension data suggested dose-dependent slowing of progression against a matched observational comparator.
Clinical Considerations
- Stage 2 patients on votoplam showed progression slowed by 28% (lower dose) and 52% (higher dose) on cUHDRS versus matched untreated Enroll-HD patients.
- Comparisons drew on an open-label extension against observational controls, not the randomized portion, limiting causal interpretation.
- Neurofilament light chain levels fell after two years, contrasting with the expected rise as Huntington’s progresses.
- Votoplam lowers HTT mRNA, reducing both healthy and mutant huntingtin; the Phase 3 readout is expected in 2030.
Practice Applications
- Recognize the efficacy signal derives from interim, non-randomized comparison.
- Interpret NfL reductions as an exploratory biomarker, not validated outcome.
- Monitor the INVEST-HD Phase 3 trial for confirmatory data.
- Avoid conveying clinical availability to families seeking disease-modifying options.
